In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

This stock is a great choice for cautious and aggressive investors.

Abstract: In this article, the input-to-state stable (ISS) problem is addressed for nonlinear delayed coupled systems on networks (CSNs) with delay-dependent impulses. Utilizing graph theory and ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

Your browser does not support the audio element. Vertex AI Workbench is a managed Jupyter environment in Google Cloud. It ships with native integration with BigQuery ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...